Authors' objectives: Lung cancer is often diagnosed at a late or advanced stage, when it has already spread to other parts of the body. The life expectancy is often less than a year. Non-small cell lung cancer is the most common type of lung cancer. Dacomitinib is a new drug being developed to treat patients with advanced non-small cell lung cancer where the cancer cells have a particular mutation (called EGFR positive). Dacomitinib is taken as a tablet once a day. A study is currently looking to see how well dacomitinib works in stopping non-small cell cancer from growing and spreading, and how safe it is to take. If dacomitinib is licensed for use in the UK, it will offer an additional treatment option for patients with advanced EGFR positive non-small cell lung cancer and may improve survival.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/dacomitinib-for-locally-advanced-or-metastatic-egfr-positive-non-small-cell-lung-cancer-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)